Gland Pharma has raised Rs 1,944 crore from anchor investors ahead of its initial share sale that opens for public subscription on Monday.

The anchor investors include the Government of Singapore, Nomura, Goldman Sachs, Morgan Stanley, SBI Mutual Fund, Axis Mutual Fund, SBI Life Insurance Company and Fidelity. ICICI Prudential Mutual Fund, HSBC Global Investment Funds, Small Cap World Fund and The Scottish Oriental Smaller Companies Trust PLC are the other investors.

Gland Pharma announced that the IPO committee of its board on November 6 and the selling shareholders in consultation with the book running lead managers to the IPO “finalised the allocation of 1,29,59,089 equity shares in aggregate to anchor investors at an allocation price of Rs 1,500 per equity share’’.

Hyderabad-based Gland Pharma is backed by China’s Fosun Pharma. Its initial public offer is the largest by a pharmaceutical company in India.